« Return to News | Awards & Advancement

Dockhorn joins SCORR Marketing

Thursday, June 13, 2013 04:01 PM

Michelle Dockhorn, M.B.A., Ph.D., an executive with extensive marketing and business development leadership experience specific to the life science industry, has joined SCORR Marketing as vice president of global markets. Dockhorn brings 20 years of experience to SCORR.

“Michelle has worked with organizations around the world, from startups to some of the biggest companies in this industry,” said Cinda Orr, SCORR president and chief executive officer. “By applying her vast experience, she has helped them build dynamic marketing programs, increase their sales and grow their businesses. Michelle understands the complexities of the drug development services industry, and our clients will find her knowledge and experience to be a great resource.”

Dockhorn began her career in drug development with National Medical Research (now SciRex), in data management, statistics, medical writing and quality assurance. She was a clinical scientist for Bristol-Myers Squibb before joining PRA, where she became vice president of global business development.

Dockhorn has served as an executive consultant in marketing, sales and business development roles for several companies in the drug development services industry, including Focus Bio-Inova, Nextrials, Logical Therapeutics, CR and Trio Clinical Research, which has since become a part of Aptiv Solutions.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.